Essential Site Maintenance: Authorea-powered sites will be updated circa 15:00-17:00 Eastern on Tuesday 5 November.
There should be no interruption to normal services, but please contact us at [email protected] in case you face any issues.

loading page

A case of hepatitis E that developed during chemotherapy for malignant lymphoma and responded to ribavirin
  • +5
  • Seiya Hashimoto,
  • Hirofumi Fukuda,
  • Kohei Takeda,
  • Keiichi Uchida,
  • Fumiaki Sanuki,
  • Takashi Akiyama,
  • Eisei Kondo,
  • Hideho Wada
Seiya Hashimoto
Kawasaki Ika Daigaku
Author Profile
Hirofumi Fukuda
Kawasaki Ika Daigaku

Corresponding Author:[email protected]

Author Profile
Kohei Takeda
Kawasaki Ika Daigaku
Author Profile
Keiichi Uchida
Kawasaki Ika Daigaku
Author Profile
Fumiaki Sanuki
Kawasaki Ika Daigaku
Author Profile
Takashi Akiyama
Kawasaki Ika Daigaku
Author Profile
Eisei Kondo
Kawasaki Ika Daigaku
Author Profile
Hideho Wada
Kawasaki Ika Daigaku
Author Profile

Abstract

The main differentials in cases of sudden elevation of hepatic enzyme levels during immunochemotherapy are reactivation of hepatitis B virus or drug-induced liver injury. Here, we report a case of acute liver injury caused by hepatitis E virus (HEV) during chemotherapy for malignant lymphoma, wherein the patient was successfully treated and completed chemotherapy. A 57-year-old woman visited her local doctor because she felt light and tired. The patient underwent lower gastrointestinal endoscopy and was diagnosed with a malignant lymphoma of the small intestine (diffuse large B-cell lymphoma). The patient had a history of oral consumption of undercooked pork liver to improve anemia and was diagnosed with acute hepatitis E. Since the patient responded to chemotherapy, she was treated with single-agent ribavirin while continuing chemotherapy, resulting in a sustained virological response. Even during treatment with immunosuppressive drugs, if appropriate treatment for hepatitis E can be administered, the patient can be fully treated without interruption. The patient was able to complete chemotherapy adequately without interruption of treatment, which was a clinically beneficial result.
22 May 2023Submitted to Cancer Reports
23 May 2023Submission Checks Completed
23 May 2023Assigned to Editor
23 May 2023Review(s) Completed, Editorial Evaluation Pending
24 May 2023Editorial Decision: Revise Major
05 Jul 20231st Revision Received
12 Jul 2023Assigned to Editor
12 Jul 2023Review(s) Completed, Editorial Evaluation Pending
12 Jul 2023Submission Checks Completed
13 Jul 2023Reviewer(s) Assigned
03 Aug 2023Editorial Decision: Revise Minor
16 Aug 20232nd Revision Received
22 Aug 2023Submission Checks Completed
22 Aug 2023Assigned to Editor
22 Aug 2023Review(s) Completed, Editorial Evaluation Pending
19 Sep 2023Reviewer(s) Assigned
29 Sep 2023Editorial Decision: Accept